Doxorubicin

Doxorubicin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Peripheral T Cell Lymphoma、DLBCL - Diffuse Large B Cell Lymphoma、Angioimmunoblastic T-cell Lymphoma、Enteropathy-Associated T-Cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Doxorubicin 研究

• Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

  II 期招募中South KoreaNCT06184009

• Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

  不适用招募中西班牙NCT07624838

• Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

  I 期招募中美国NCT05210374

• PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

  II 期招募中美国NCT06245889

• Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

  I 期招募中美国NCT04301076

• DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

  I 期 / II 期招募中中国NCT07059650

• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  III 期招募中美国澳大利亚加拿大新西兰NCT03959085

• A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

  I 期 / II 期招募中中国NCT06840002

• RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL

  II 期招募中中国NCT06674096

• Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer

  II 期招募中中国NCT07635342

• A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.

  I 期 / II 期招募中西班牙NCT07460986

• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

  II 期招募中美国NCT01042379

• Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

  不适用招募中美国NCT04199026

• A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

  不适用招募中中国NCT05899621

• Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

  II 期招募中中国NCT04138719

• Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

  I 期 / II 期招募中中国NCT06829771

• Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

  I 期 / II 期招募中中国NCT04432714

• Preventive Use of PIPAC in Locally Advanced Gastric Cancer.

  不适用招募中KazakhstanNCT06784765

• FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  I 期 / II 期招募中澳大利亚奥地利比利时CzechiaNCT04625907

• Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

  III 期招募中中国NCT05159193

• The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

  III 期招募中中国NCT05018520

• Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  III 期招募中美国日本NCT07564141

• Venetoclax Basket Trial for High Risk Hematologic Malignancies

  I 期招募中美国NCT05292664

• Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

  II 期招募中美国NCT06745076

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。